Kiniksa Pharmaceuticals International, plc
KNSA
Rank in Stocks
#2962
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Share Price
$79.61
Market Cap
$6.21B
Change (1 day)
1.30%
Change (1 year)
106.02%
Country
GB
Trade Kiniksa Pharmaceuticals International, plc (KNSA)
Category
Healthcare
Earnings for Kiniksa Pharmaceuticals International, plc (KNSA)
Earnings in Jun 2026 TTM: $114.25M
According to Kiniksa Pharmaceuticals International, plc latest financial reports the company's current earnings are $114.25M. In 2023 the company made an earning of $-16.65M, a decrease compared to its 2022 earnings that were of $11.03M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Kiniksa Pharmaceuticals International, plc from 2016 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $114.25M | -416.03% |
| 2024 | $-36.15M | 117.10% |
| 2023 | $-16.65M | -251.02% |
| 2022 | $11.03M | -107.04% |
| 2021 | $-156.54M | 0.20% |
| 2020 | $-156.23M | -4.69% |
| 2019 | $-163.91M | 58.46% |
| 2018 | $-103.44M | 59.46% |
| 2017 | $-64.87M | 171.01% |
| 2016 | $-23.94M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $1.35B | 1,081.48% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -76.92% |
US
|
